Verteporfin inhibits lipopolysaccharide-induced inflammation by multiple functions in RAW 264.7 cells

Yuting Wang, Lei Wang, James T.F. Wise, Xianglin Shi, Zhimin Chen

Research output: Contribution to journalArticlepeer-review

14 Scopus citations


Inflammation is a physiologic response to damage triggered by infection, injury or chemical irritation. Chronic inflammation produces repeated damage to cells and tissues, which can induce a variety of human diseases including cancer. Verteporfin, an FDA approved drug, is used for the treatment of age-related macular degeneration. The anti-tumor effects of verteporfin have been demonstrated by a number of studies. However, fewer studies focus on the anti-inflammatory functions of this drug. In this study, we investigated the anti-inflammatory effects and potential mechanisms of verteporfin. The classic lipopolysaccharide (LPS)-induced inflammation cell model was used. RAW 264.7 cells were pre-treated with verteporfin or vehicle control, followed by LPS stimulation. Verteporfin inhibited IL-6 and TNF-α at mRNA and protein expression levels. This effect was mediated through inhibition of the NF-κB and JAK/STAT pathways. Finally, verteporfin exhibited an anti-inflammation effect by crosslinking of protein such as NF-κB p65, JAK1, JAK2, STAT1, or STAT3 leading to inflammation. Taken together, these results indicate that verteporfin has the potential to be an effective therapeutic agent against inflammatory diseases.

Original languageEnglish
Article number114852
JournalToxicology and Applied Pharmacology
StatePublished - Jan 15 2020

Bibliographical note

Publisher Copyright:
© 2019 Elsevier Inc.


  • Inflammation
  • LPS
  • RAW 264.7
  • Verteporfin

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology


Dive into the research topics of 'Verteporfin inhibits lipopolysaccharide-induced inflammation by multiple functions in RAW 264.7 cells'. Together they form a unique fingerprint.

Cite this